Wellbiotec Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 12,087.35 million compared to KRW 32,512.46 million a year ago. Net loss was KRW 64,910.32 million compared to KRW 20,880.93 million a year ago.

Basic loss per share from continuing operations was KRW 820 compared to KRW 325 a year ago. Diluted loss per share from continuing operations was KRW 820 compared to KRW 325 a year ago. Basic loss per share was KRW 820 compared to KRW 325 a year ago.